超越传统疗法:NOX4作为心肌病的有希望的目标
Nandini Dubey1, Gauri Chaturvedi1, Satnam Singh1
1Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Molecular biology reports
|July 11, 2025
概括
在心肌病中,NADPH氧化酶4 (NOX4) 驱动反应性氧物种 (ROS) 生产,导致心脏损伤. 抑制NOX4可能为心肌疾病提供新的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- 心肌病包括心肌疾病,其特点是结构和功能异常.
- 常见的类型包括扩张性和缩性心肌病变,更罕见的形式如Takotsubo和arrhythmogenic右室心肌病变.
- 病理机制包括腹腔缩,纤维化和功能障碍,通常是由压力和氧化应激引起的.
研究的目的:
- 探索NADPH氧化酶4 (NOX4) 驱动的活性氧物种 (ROS) 在各种心肌病亚型中的产生作用.
- 综合目前关于NOX4功能和心脏病理生理学中的调节机制的知识.
- 突出了解NOX4在心肌病中的治疗意义.
主要方法:
- 审查NOX4现有研究及其对心脏病理学的贡献.
- 分析NOX4在心肌细胞内,特别是线粒体内产生ROS中的作用.
- 对调查NOX4抑制或删除对心脏重塑和功能的影响的研究进行审查.
主要成果:
- NADPH氧化酶4 (NOX4) 是心肌细胞中ROS的重要来源,有助于病态心脏重塑,炎症,纤维化,亡和过度缩小.
- 由NOX4产生的ROS与各种心肌病亚型的病理生理学有关.
- 抑制或基因删除NOX4已被证明可以减轻这些有害影响.
结论:
- NOX4介导的ROS产生是心肌病进展的关键因素.
- 向NOX4为开发用于心肌病的新型治疗策略提供了一个有希望的途径.
- 进一步了解NOX4的功能和调节对于推进心肌病治疗至关重要.
相关概念视频
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
25
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
25
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:26Heart Failure Drugs: Inotropic Agents
716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716
01:30Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
01:29Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505